Press Releases

09.05.2018

4D Molecular Therapeutics Raises $90 Million Series B Financing

09.05.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

09.04.2018

Pfizer Prices $5,000,000,000 Debt Offering

08.30.2018

Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy

08.22.2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

08.20.2018

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

08.16.2018

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

08.08.2018

SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2 ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A

08.01.2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis

07.31.2018

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

07.31.2018

Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

07.24.2018

Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs